-
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)
Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
B Cells: Function, Types, Activation & Role in Immunity(Post)B Cell Types, Antigen Recognition & Activation A comprehensive guide to B cells! Introduction B cells, a vital component of the immune system, play
What is CAR T-cell therapy?(Post)CAR T-cell therapy CAR (Chimeric Antigen Receptor) T-cell Therapy is a type of cancer treatment. CAR T-cells are made in the laboratory and they have an artificially created receptor on the
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
Neutrophil Activation & NETosis(Page) Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Protocols(Page)Protocols & Assay Guides | ELISA, Multiplex, Western Blot | Assay Genie
The Intestinal Barrier: Junctions, Mucus and Permeability(Page) Targeting IL-10R: Enhancing Immune Activation in Cancer(Post)Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
Immunoassays(Page)Immunoassays: ELISA, Multiplex & ELISpot Kits | Assay Genie
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress
Abituzumab: Understanding Its Role in Cancer and Fibrosis Research(Post)Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechani
Myeloid reprogramming in the tumour microenvironment(Page) Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Cyclins and Cyclin Dependent Kinase – Review(Post)Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa
Prevention and Risk Mitigation: Strategies to Reduce Hantavirus Exposure in a Changing World(Post)As hantavirus cases continue to rise globally, the question becomes not just how to detect infections, but how to prevent them in the first place. Recent epidemiological investigations across Califor